Patient-Derived Xenograft Model Market (By Tumor Type: Lung Cancer, Pancreatic Cancer, Prostrate Cancer, Breast Cancer, Other Cancer ; By Application; By End-user) - Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook and Forecast 2022-2030

The global patient-derived xenograft model market was surpassed at USD 140.3 million in 2021 and is expected to hit around USD 552.48 million by 2030, growing at a CAGR of 16.45% from 2022 to 2030.

Patient-Derived Xenograft Model Market Size 2021 to 2030

Report Summary

The global patient-derived xenograft model market is anticipated to reflect a considerable growth rate across the forecast period. Some of the major factors driving the patient-derived xenograft model market include the rise in the number of researches globally, growing burden of cancer, promoting the demand for new treatment options; and significant demand for personalized therapies worldwide.

PDX models have certain advantages, such as the ability to partially recapitulate the tumor microenvironment. These models maintain genetic and histologic features of origin, have high predictive value and also can be used as a metastatic model. These factors of the PDX model further support the growth of the patient-derived xenograft model market.

Public organizations globally are taking initiatives to improve research activities globally. For instance, in August 2022, the NIH provided the SBIR grant to AVM Biotechnology to conduct research on the effect of drugs on lymphoma. Similar initiatives by public organizations in the future are expected to promote the market's growth to a great extent.

During the COVD-19 pandemic, cancer research was halted as the majority of studies were focused on developing drugs for COVID-19. However, in the post-pandemic period, the majority of the focus of researchers is on developing innovative therapies for cancer. This is expected to support the growth of the patient-derived xenograft model market in the post-pandemic period.  

Based on end-user, the pharmaceutical and biopharmaceutical companies segment held a substantial share in the market. The growing number of research projects by these companies in the areas of personalized medicine and cancer are the key factors contributing to the growth of the segment market.

North America held a significant share in the market in 2021. The growing number of research studies in the region, significant number of funding for preclinical researches and growing demand for innovative therapies are some of the key factors driving the patient-derived xenograft model market in North America. The surge in the cancer burden in the region further supports the growth of the North America patient-derived xenograft model market.

Scope of The Report

Report Coverage Details
Market Size in 2021 USD 140.3 million
Revenue Forecast by 2030 USD 552.48 million 
Growth rate from 2022 to 2030 CAGR of 16.45%
Base Year 2021
Forecast Period 2022 to 2030
Segmentation Tumor Type, Application, End User, Region
Companies Covered

Charles River Laboratories; THE JACKSON LABORATORY; Crown Bioscience.; Altogen Labs; Envigo; WuXi AppTec; Oncodesign; Hera Biolabs; XenTech; and Abnova Corporation.


Key Players

  • Charles River Laboratories
  • Crown Bioscience.
  • Altogen Labs
  • Envigo
  • WuXi AppTec
  • Oncodesign
  • Hera Biolabs
  • XenTec
  • Abnova Corporation.

Market Segmentation

  • By Tumor Type
    • Lung Cancer
    • Pancreatic Cancer
    • Prostrate Cancer
    • Breast Cancer
    • Other Cancer
  • By Application
    • Preclinical Studies
    • Biomarker Analysis
    • Cancer Research
  • By End User
    • Pharmaceutical and Biopharmaceutical Comapnies
    • Accademic and Research Institutes
    • CRO’s and CDMO’s
  • By Region
    • North America
    • Europe
    • Asia Pacific
    • Latin America
    • Middle East & Africa

Report Detail

Proceed To Buy

USD 3500
USD 7000